14.00
-7.59%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ContextLogic Holdings
From its filings with the US Securities and Exchange Commission
ContextLogic Holdings is based in Oakland, California and is incorporated in Delaware. Its shares trade on OTC under the ticker LOGC. The SEC classifies its business as mining & quarrying of nonmetallic minerals (no fuels). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $23.0m. At that date it held total assets of $218.0m and shareholders' equity of $133.0m.
We are a business ownership platform designed from first principles to combine the structural advantages of permanent public capital with the operating discipline, alignment, and long-term orientation typically associated with private ownership. Our mission is to build a portfolio of high-quality, niche, and competitively advantaged businesses that generate sustainable, growing free cash flow that can be reinvested over long time horizons.
Our origins trace to the former Wish.com business, which was divested following a multi-year decline driven by structural challenges in its underlying business model, leaving us with balance sheet liquidity of $162 million. Prior to the divestiture, the Company preserved approximately $2.9 billion of federal net operating losses ("NOLs") and other tax attributes.
In 2025, investment funds advised by BC Partners Advisors LP ("BC Partners") and Abrams Capital Partners I, L.P., a Delaware limited partnership ("ACP I") and Abrams Capital Partners II, a Delaware limited partnership ("ACP II", together with ACP I, "Abrams Capital) partnered to recapitalize ContextLogic, and ContextLogic Holdings, LLC, a Delaware limited liability company and our majority owned subsidiary (“Holdings”), to acquire US Salt (such acquisition, the “US Salt Acquisition”) and architect a new platform based on aligned ownership, decentralized operations, and disciplined capital deployment.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Oct 2018
- Employees
- 206
- Website
- logicbio.com ↗
- Head office
- 2648 INTERNATIONAL BLVD., OAKLAND, CA, 94601
- Incorporated in
- DE
- Classification
- Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Richard MoscickiIndependent Chairman of the Board$113,641
- Mr. Frederic ChereauPresident, Chief Executive Officer, Director$2.2m
- Ms. Cecilia JonesChief Financial Officer, Treasurer$2.0m
- Ms. Janice OlsonSenior Vice President - Strategy and Portfolio Management
- Dr. Mariana NachtChief Scientific Officer$946,300
- Ms. Andrea PaulGeneral Counsel, Company Secretary
- Dr. Daniel GruskinChief Medical Officer$1.5m
- Dr. Leon ChenIndependent Director$103,281
- Mr. Mark EnyedyIndependent Director$82,016
- Mr. Jeff GoaterIndependent Director$76,766
- Ms. Susan KahnIndependent Director$40,313
- Ms. Daphne KarydasIndependent Director$79,641
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 23
- Environment
- 21
- Social
- 42
- Governance
- 6
- Women in the workforce
- 50%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is focused on developing medicines for rare diseases with significant unmet medical need.
- GeneRide technology platform integrates corrective genes into patient genome for stable therapeutic effect.
- Lead product candidate LB-001 is in development for Methylmalonic Acidemia treatment.
Weaknesses
- Company employs only 206 employees as per provided data.
- IPO occurred in 2018-10-19 which may indicate limited market experience.
- Website domain suggests a different company name than the one provided.
Opportunities
- Development of multiple product candidates including LB-001, LB-101, LB-201 and LB-301.
- Targeting rare liver disorders in pediatric patients represents a niche market with potential growth.
- Biotechnology sector shows ongoing interest in genome editing therapies.
Threats
- Source description contains conflicting information about company headquarters location (Lexington, Massachusetts vs. Lexington, US).
- Source description states 41 full-time employees while provided data states 206 employees.
- Source description mentions different product names (LB-001, LB-101 etc.) but does not confirm all are active development candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.